- Home
- HSCS vs ATXI Comparison
HSCS vs ATXI Comparison
Compare HSCS & ATXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- ATXI
- Stock Information
- Founded
- HSCS 2007
- ATXI 2015
- Country
- HSCS United States
- ATXI United States
- Employees
- HSCS N/A
- ATXI N/A
- Industry
- HSCS Medical Specialities
- ATXI Biotechnology: Pharmaceutical Preparations
- Sector
- HSCS Health Care
- ATXI Health Care
- Exchange
- HSCS Nasdaq
- ATXI Nasdaq
- Market Cap
- HSCS 2.7M
- ATXI 3.0M
- IPO Year
- HSCS 2022
- ATXI 2017
- Fundamental
- Price
- HSCS $2.67
- ATXI $2.01
- Analyst Decision
- HSCS Strong Buy
- ATXI Strong Buy
- Analyst Count
- HSCS 1
- ATXI 1
- Target Price
- HSCS $15.00
- ATXI $56.25
- AVG Volume (30 Days)
- HSCS 26.2K
- ATXI 47.5K
- Earning Date
- HSCS 12-12-2024
- ATXI 11-14-2024
- Dividend Yield
- HSCS N/A
- ATXI N/A
- EPS Growth
- HSCS N/A
- ATXI N/A
- EPS
- HSCS N/A
- ATXI N/A
- Revenue
- HSCS $18,600.00
- ATXI N/A
- Revenue This Year
- HSCS $8,948.39
- ATXI N/A
- Revenue Next Year
- HSCS $27.27
- ATXI N/A
- P/E Ratio
- HSCS N/A
- ATXI N/A
- Revenue Growth
- HSCS 853.85
- ATXI N/A
- 52 Week Low
- HSCS $2.36
- ATXI $1.60
- 52 Week High
- HSCS $29.00
- ATXI $26.48
- Technical
- Relative Strength Index (RSI)
- HSCS 40.14
- ATXI 44.02
- Support Level
- HSCS $2.53
- ATXI $1.60
- Resistance Level
- HSCS $2.76
- ATXI $2.06
- Average True Range (ATR)
- HSCS 0.17
- ATXI 0.15
- MACD
- HSCS 0.02
- ATXI -0.00
- Stochastic Oscillator
- HSCS 22.83
- ATXI 50.74
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.